Blog

Company News

Industry Trends

Laws Regulations

All Categories >

21

2023-02

Industry Research | Cell and Gene Therapy

Cell and gene therapy is an emerging therapeutic approach that involves the delivery of exogenous genetic material into target cells to modify or manipulate gene expression, thereby altering cellular biological properties and achieving therapeutic outcomes.

2023-02-21

He Yousheng

15

2023-02

Hycells Birthday Celebration | Wishing you a wonderful holiday and joyful moments together!

On this auspicious occasion, may all be well and in harmony with the times. With each passing year, we share in the joy together. Growth arrives unexpectedly, yet birthdays come as scheduled. Behind every beautiful moment lies relentless effort and dedication. Each birthday is worthy of our heartfelt anticipation and celebration.

2023-02-15

He Yousheng

02

2023-02

The National Medical Products Administration Has Officially Released the Guiding Principles for Quality Management in the Production of Cell Therapy Products (Trial)

On October 31, the Verification Center of the National Medical Products Administration officially released the “Guidance on Quality Management for the Manufacture of Cell Therapy Products (Trial),” which comprises 13 chapters and covers such topics as the basic principles of GMP management for cell therapy products, personnel, premises, facilities and equipment, donor screening and donor-derived materials, raw materials and products, manufacturing management, quality management, and product traceability systems.

2023-02-02

He Yousheng

02

2023-02

You can’t have it all: being a CXO and developing innovative drugs.

China’s previous wave of innovative-drug enthusiasm reached a milestone with the approval and launch of several large-molecule biosimilars, only to cool off rapidly thereafter once these products were included in the national medical insurance scheme. The interim outcome of that boom was the listing of roughly 20 innovative-drug companies on the Hong Kong stock exchange, nearly all of which had PD-1 candidates in their pipelines. In this highly “me-too” market, regardless of whether a product is covered by insurance, as long as it delivers some clinical benefit, price becomes the sole metric for valuation. Among the rising stars—Xinda, Junshi Biosciences, and BeiGene—as well as the established player Hengrui Medicine, all core PD-1 products have since been added to the national reimbursement list. Yet in 2021, the combined sales of these four companies’ PD-1 products—about RMB 9 billion—still amounted to little more than a fraction of Merck’s PD-1 blockbuster Keytruda, which generated US$17.1 billion in revenue. Despite this, the aggregate market capitalization of these firms at one point surpassed Merck’s, clearly signaling a bubble.

2023-02-02

He Yousheng

06

2023-01

Holiday Notice for the Spring Festival at Hycells Biotechnology!

2023-01-06

He Yousheng

21

2022-12

Ding! Please sign for your Christmas Eve gift!

With the adjustment of epidemic prevention and control measures, Shanghai has entered a new phase in its fight against the virus. On this invisible battlefield, each of us—striving to live well and working diligently—is a warrior. We are deeply grateful to every colleague who remains steadfast at their post or stays home, tirelessly battling the virus while continuing to do their job. You are all truly outstanding.

2022-12-21

He Yousheng
< 1...202122...24 >